VRTX Q4 2023 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.5B+9.3% YoY

Gross Profit

$2.1B85.4% margin

Operating Income

$989M39.3% margin

Net Income

$969M38.5% margin

EPS (Diluted)

$3.71

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

$235M

Free Cash Flow

$177M

Stock-Based Comp.

$209M

Balance Sheet

Total Assets

$22.7B

Total Liabilities

$5.1B

Stockholders' Equity

$17.6B

Cash & Equivalents

$10.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.3B	+9.3%
Gross Profit	$2.1B	$2.0B	+6.5%
Operating Income	$989M	$1.0B	-4.4%
Net Income	$969M	$819M	+18.3%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.3B93%

KALYDECO

$112M4%

ORKAMBI

$44M2%

SYMDEKO/SYMKEVI

$28M1%

Geographic Segments

UNITED STATES

$1.6B63%

Europe

$735M29%

Other, Non U.S.

$208M8%